According to a recent announcement on the National Medical Products Administration (NMPA) website, Haikou Qili Pharmaceutical has received approval for its supplemental application for the consistency evaluation of Piperacillin Sodium and Tazobactam Sodium for injection.

Data from Menet shows that in 2023, the terminal market of China's public medical institutions recorded more than RMB 7 billion in sales of piperacillin-tazobactam injections.

To date, Qili Pharmaceutical has 11 products that have passed consistency evaluation.

Indications of the Approved Product

Information on the delivery of drug approval documents on December 18, 2024

Piperacillin Sodium and Tazobactam Sodium for injection is indicated for moderate to severe infections caused by susceptible strains in conditions such as: pneumonia, urinary tract infections, intra-abdominal infections, skin and soft-tissue infections, bacterial septicemia, endometritis or pelvic inflammatory disease, bone and joint infections, etc.

Recent Sales of Piperacillin-Tazobactam Injections in China's Public Medical Institutions (Unit: 10,000 RMB)

Source: Menet - Competitive Landscape of Drug Use in China's Public Medical Institution Terminal Market

Menet data shows that piperacillin-tazobactam injections generated over RMB 7 billion in 2023 across China's public medical institutions, including: urban public hospitals, county-level public hospitals, community health centers, township health centers. The leading companies by market share were Ruiyang Pharmaceutical, United Laboratories, and Shandong Anxin Pharmaceutical.

So far, 22 companies—including Haikou Qili, Ruiyang, Chengdu Better Pharmaceuticals, and North China Pharmaceutical—have passed consistency evalution for piperacillin-tazobactam injections.

Qili Pharmaceutical's Portfolio

Source: Menet Consistency Evaluation Database

As of now, Qili Pharmaceutical has 11 products that have passed evaluation, including 8 systemic anti-infective drugs. Two of its key cephalosporin products—Ceftzidime for injection and Ceftriaxone Sodium for injection— each recorded over RMB 2 billion in sales in 2023 within China's public medical institution market.

Source: 

NMPA official website; Menet Database

Note: Menet's "China Public Medical Institution Terminal Landscape" covers public hospitals and health centers only, excluding private hospitals and clinics. Sales data is calculated based on average terminal retail pricing.

Article originally from Menet. Please contact us for removal if required.